TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35633589
Drug: Hyperchloremia (defined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperchloremia (defined as 110 mmol/L or greater) with two or more occurrences within 48 hours
Study: 33899452
Drug: High-intensity laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity laser therapy
Study: 33899452
Drug: Fractional radiofrequency
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional radiofrequency therapy
Study: 33899452
Drug: Combined methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined methods (high-intensity laser therapy or micro-needling in combination with peels, fillers, PRP injection)
Study: 33899452
Drug: Micro-needling as
Normalized name: Salicylic Acid 0.002 TOPICAL PATCH [Egg micro needle soothing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-needling as monotherapy
Study: 33310432
Drug: 5 U-Turn
Normalized name: TURNIP
DrugBank: Turnip (DB10652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 U-Turn Test (5UTT) - smartphone-based assessment of U-turn speed, self-administered daily for 14 days
Study: 36727801
Drug: Half-dose photodynamic
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose photodynamic therapy
Study: 35999026
Drug: Marstacimab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marstacimab (300 mg, 150 mg, or 450 mg weekly doses based on inhibitor status)
Study: 33753445
Drug: Prophylactic low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic low molecular weight heparin (LMWH)
Study: 34752255
Drug: Electric 3D
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric 3D toothbrush (Oral-B Pro-1000 with Oral-B Ortho head)
Study: 34752255
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (Oral-B Orthodontic brush)
Study: 34913281
Drug: Antioxidant-rich dietary
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant-rich dietary intervention (3 meal boxes daily for 4 weeks)
Study: 34602400
Drug: Celecoxib combined
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib combined with glucosamine hydrochloride therapy
Study: 34602400
Drug: Celecoxib tablet
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib tablet therapy
Study: 36307989
Drug: Topical gentamicin
Normalized name: gentamicin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gentamicin cream delivered via platform wound device (PWD)
Study: 32246899
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of 4-fluoroamphetamine (4-FA)
Study: 32246899
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of 4-fluoroamphetamine (4-FA) in 150 mL Royal Club bitter lemon drink
Study: 32585392
Drug: Turmeric and
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric and mefenamic acid (500 mg and 250 mg respectively)
Study: 32585392
Drug: Turmeric (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric (500 mg)
Study: 32585392
Drug: Turmeric and
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric and mefenamic acid combination
Study: 36251574
Drug: Neoadjuvant dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVACx6)
Study: 35820575
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT; n = 24)
Study: 33978382
Drug: miR‐182 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: miR‐182 inhibitor
Study: 33038141
Drug: 10 μg vaginal
Normalized name: Mycelex-G Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg vaginal estrogen therapy (ET) for 52 weeks
Study: 32543021
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 μg) administered three times daily for 26 weeks
Study: 32543021
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered three times daily for 26 weeks
Study: 33402377
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy Skills Scale
Study: 36000934
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment (8 rifamycin and 26 isoniazid monotherapy)
Study: 33842907
Drug: Selenite 200
Normalized name: selenite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenite 200 μg
Study: 33842907
Drug: Selenite 50
Normalized name: selenite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenite 50 μg
Study: 35868015
Drug: High-carbohydrate diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate diet (CHO; 1 g CHO·kg ‐1 ·h ‐1)
Study: 35868015
Drug: Low-carbohydrate placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate placebo diet (PLA; <0.1 g CHO·kg ‐1 ·h ‐1)
Study: 32799726
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and azithromycin
Study: 32851421
Drug: CDP-choline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline (500 mg) with galantamine (16 mg)
Study: 33577559
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of antiretroviral treatment (ART)
Study: 38810093
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg)
Study: 35190468
Drug: 10 mL 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 0.5% bupivacaine plus 133 mg liposomal bupivacaine (LB)
Study: 35190468
Drug: 20 mL of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.5% bupivacaine
Study: 33548194
Drug: CoronaVac 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac 1.5 µg
Study: 33548194
Drug: CoronaVac 3
Normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac 3 µg
Study: 33548194
Drug: CoronaVac 6
Normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac 6 µg
Study: 33548194
Drug: CoronaVac 3
Normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac 3 µg (phase 1)
Study: 33548194
Drug: CoronaVac 6
Normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac 6 µg (phase 1)
Study: 32402509
Drug: Definitive high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definitive high-dose radiation therapy (RT)
Study: 35294969
Drug: Daily multivitamin-multimineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multivitamin-multimineral (MVM) supplement
Study: 36297081
Drug: CAF*TAU (co‐ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF*TAU (co‐ingestion of 3 g single dose of taurine and 6 mg/kg of caffeine)
Study: 36297081
Drug: TAU (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU (3 g single dose of taurine)
Study: 33788483
Drug: Irrelevant acupoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrelevant acupoint prescription (Feiyang, Heding, Yingu, Tianfu, Xiabai)
Study: 35438754
Drug: Degarelix (1-time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix (1-time subcutaneous dose of 240 mg)
Study: 32223601
Drug: Targeted Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted Medication Therapy Management (tMTM) intervention
Study: 33734000
Drug: Repetitive Transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) and Bright Light Therapy (BLT)
Study: 33392885
Drug: Positive anti‐β2‐GPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive anti‐β2‐GPI antibody
Study: 33392885
Drug: Negative anti‐β2‐GPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative anti‐β2‐GPI antibody
Study: 32776518
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal therapy with closed mouth
Study: 32776518
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal therapy with open mouth
Study: 35506888
Drug: Paediatric Autism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paediatric Autism Communication Therapy (PACT) - 12 sessions
Study: 36191485
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tea polyphenols (TP)
Study: 36191485
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tea polyphenols (TP)
Study: 36191485
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tea polyphenols (TP)
Study: 34274136
Drug: Cabazitaxel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (25 mg/m2 plus prednisone and granulocyte colony-stimulating factor)
Study: 33449432
Drug: Parent training
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent training intervention supporting home oral hygiene and dental visits
Study: 34779349
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (1 year of 150 min weekly combined strength and endurance exercise)
Study: 33517741
Drug: US-guided injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided injection
Study: 33191260
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP) 650 mg
Study: 35331943
Drug: smartphone App
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: smartphone App delivery of caregiver skills with Mentalizing Imagery Therapy (MIT)
Study: 33811034
Drug: Subcutaneous denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous denosumab 60 mg every 6 months for 24 months
Study: 36064438
Drug: AutoKinetics dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: AutoKinetics dosing for other antibiotics (meropenem, vancomycin, ceftriaxone)
Study: 36064438
Drug: AutoKinetics dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: AutoKinetics dosing and Standard dosing (Control)
Study: 36064438
Drug: Higher dosing
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosing (AutoKinetics)
Study: 35104279
Drug: Aspirin 80
Normalized name: aspirin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 80 mg daily
Study: 33025656
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg for 1 year
Study: 33025656
Drug: LDL levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL levels more than 90 mg/dl in the first year
Study: 33025656
Drug: LDL levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL levels less than 90 mg/dl in the first year
Study: 33048462
Drug: NobelReplace Tapered
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NobelReplace Tapered implants (Nobel Biocare, Sweden)
Study: 33048462
Drug: NobelSpeedy implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: NobelSpeedy implants (Nobel Biocare, Sweden)
Study: 34246130
Drug: Methacholine challenge
Normalized name: Methacholine Challenge Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine challenge test (MCT) with doses of PC20 ? 8 mg/ml
Study: 34246130
Drug: Methacholine challenge
Normalized name: Methacholine Challenge Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine challenge test (MCT) with doses of PC20 ? 2 mg/ml
Study: 34246130
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of asthmatic wheeze and BHR
Study: 36111910
Drug: Concurrent aerobic
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent aerobic and resistance exercises (three sessions per week for twelve weeks on alternative days)
Study: 36111910
Drug: Regular lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular lifestyle practices and medical treatment without any exercise intervention
Study: 33775175
Drug: Enhanced treatment-as-usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment-as-usual control
Study: 34223660
Drug: CBD 200
Normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [SOMBRA PLUS CBD 2000MG COOL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD 200 mg
Study: 34223660
Drug: CBD 800
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD 800 mg
Study: 35776835
Drug: Tapentadol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol (50 mg extended-release tablets)
Study: 36099926
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg, intravenous, once every 3 weeks for 16 cycles or 1 year)
Study: 36099926
Drug: Placebo (intravenous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous, once every 3 weeks for 16 cycles or 1 year)
Study: 34144032
Drug: High-dose Erythropoietin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Erythropoietin for Asphyxia and Encephalopathy Trial
Study: 32921425
Drug: Melatonin (MEL)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (MEL) therapy as an add-on treatment, 2 to 10 mg, for a long period.
Study: 32921425
Drug: Melatonin (MEL)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (MEL) therapy, 2 mg slow release, 1 to 2 hours before bedtime, for 3 to 12 weeks.
Study: 32921425
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy used 12 hours before melatonin treatment.
Study: 35578445
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of tofogliflozin (20 mg) and pioglitazone (15–30 mg)
Study: 32648392
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (estazolam 1-2 mg per night for 4 weeks)
Study: 32211798
Drug: Milk8 (8.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk8 (8.8 g milk protein/d, 100 kcal/d)
Study: 32211798
Drug: Milk/rice (4.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk/rice (4.4 g milk and 4.4 g rice protein/d, 100 kcal/d)
Study: 32211798
Drug: Milk4 (4.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk4 (4.4 g milk protein/d, 48 kcal/d)
Study: 34370858
Drug: Ultra-long downregulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-long downregulation with GnRH agonist (triptorelin depot) for at least 3 months followed by ART stimulation.
Study: 34370858
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group underwent ART stimulation in a classical long agonist protocol using oral contraceptives.
Study: 32443343
Drug: Twice-weekly MHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly MHD
Study: 32443343
Drug: 3-times-weekly MHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-times-weekly MHD
Study: 34346046
Drug: Duloxetine 20mg/daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 20mg/daily
Study: 34346046
Drug: Solifenacin 10mg/daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 10mg/daily
Study: 35346339
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal therapy for a minimum of 16 hours immediately post extubation
Study: 35346339
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy for a minimum of 16 hours immediately post extubation
Study: 35346339
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal therapy
Study: 33662489
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intermittent vitamin D3 supplementation
Study: 33662489
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose B12 supplementation
Study: 34740538
Drug: L-Carnitine 50
Normalized name: L-Carnitine 500mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Carnitine 50 mg/kg
Study: 32818963
Drug: VT‐1161 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: VT‐1161 300 mg once daily for 3 days
Study: 32818963
Drug: VT‐1161 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: VT‐1161 600 mg once daily for 3 days
Study: 32818963
Drug: VT‐1161 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: VT‐1161 600 mg twice daily for 3 days
Study: 32818963
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg (single dose)
Study: 32929891
Drug: Azithromycin 250
Normalized name: azithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 250 mg, 3 times per week for 16 weeks
Study: 32929891
Drug: Azithromycin 250
Normalized name: azithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 250 mg, 3 times per week for 16 weeks (in AERD-negative patients)
Study: 35236423
Drug: Low-fat milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat milk fortified with 1500 IU nano-encapsulated vitamin D3 (200 mL/day)
Study: 35236423
Drug: Low-fat yogurt
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat yogurt fortified with 1500 IU nano-encapsulated vitamin D3 (150 g/day)
Study: 35236423
Drug: Simple milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple milk (200 mL/day)
Study: 35236423
Drug: Simple yogurt
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple yogurt (150 g/day)
Study: 32494991
Drug: Pharmacist-administered deprescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-administered deprescribing intervention
Study: 33905144
Drug: Subcutaneous nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous nerve field stimulation in combination with optimized medical management
Study: 33894725
Drug: Reduning injection
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduning injection (20 mL/day for 14 days)
Study: 33894725
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine treatment without Reduning injection)
Study: 33894725
Drug: Reduning injection
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduning injection
Study: 33764833
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg or 100 mg of water-soluble CoQ10 (total daily dose, 100 mg [n = 5] or 200 mg [6])
Study: 34642106
Drug: Thought Field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thought Field Therapy (single session)
Study: 34861430
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg/d) and Vitamin D (1000 IU/d) supplementation
Study: 34793441
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg iOWH032 every 8 hours for 3 days
Study: 34089515
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with erythrosine, 15 min incubation, 15 min continuous light irradiation
Study: 34089515
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with erythrosine, 2 min incubation, 15 min continuous light irradiation
Study: 34089515
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with erythrosine, 15 min incubation, fractionated light (5 x 30 sec)
Study: 34089515
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with erythrosine, 2 min incubation, fractionated light (5 x 30 sec)
Study: 33993346
Drug: Nebulization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization of 1 µg/kg dexmedetomidine (DEX) diluted in 4 mL 0.9% saline twice daily
Study: 33993346
Drug: Nebulization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization of 4 mL 0.9% saline
Study: 34752934
Drug: Accelerated intermittent
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated intermittent theta-burst stimulation (iTBS) administered to the left dorsolateral prefrontal cortex (DLPFC) for 14 days
Study: 34337507
Drug: Intravesical HA/CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical HA/CS plus an oral formulation of curcumin, quercetin, HA, and CS (group A)
Study: 35406085
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral nutritional supplement (ONS)
Study: 34224214
Drug: Fexofenadine-montelukast fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine-montelukast fixed-dose combination tablet (120 mg fexofenadine and 10 mg montelukast)
Study: 33627186
Drug: Integrative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative therapy based on Ayurveda and Yoga
Study: 33627186
Drug: Modern western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern western medicine (MWM)
Study: 33861657
Drug: Silymarin 140
Normalized name: silymarin 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 140 mg three times a day